Lab21 gets first Chinese approval for syphilis assay
This article was originally published in Clinica
Executive Summary
An assay used in syphilis screening developed by UK firm Lab21 has been approved in China. The assay detects Treponema pallidum haemagglutination (TPHA). The Chinese market for in vitro diagnostics is worth around $1.5bn and is expanding by 15% annually, according to Lab21. "Our TPHA assay is already the leading syphilis assay in a number of key blood screening markets and we are delighted to make it available in another key region," the Cambridge-based company said.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.